CSF neurofilament levels: a potential prognostic marker in Guillain-Barré syndrome.
Long-term morbidity from Guillain-Barré syndrome (GBS) is caused by axonal damage. This prospective study demonstrated that neurofilaments (NfHs), a biomarker for axonal damage, were of prognostic value in GBS. CSF NfH levels correlated with the F score and Medical Research Council summed score and were higher in patients with neurophysiologic evidence of axonal degeneration compared to those without. Pathologically high CSF NfH levels (>0.73 ng/mL) predicted worse motor and functional outcome.
Petzold
A
A
Department of Neuroimmunology, Institute of Neurology and Tavistock Intensive Care Unit, National Hospital for Neurology and Neurosurgery, London, UK. a.petzold@ion.ucl.ac.uk
Hinds
N
N
Murray
N M F
NM
Hirsch
N P
NP
Grant
D
D
Keir
G
G
Thompson
E J
EJ
Reilly
M M
MM
D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D020275:Guillain-Barre Syndrome / Q000134:cerebrospinal fluid* / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009431:Neural Conduction / Q000502:physiology; D016900:Neurofilament Proteins / Q000134:cerebrospinal fluid*; D011379:Prognosis; D012189:Retrospective Studies
D016756:Immunoglobulins, Intravenous; D016900:Neurofilament Proteins; C051774:neurofilament protein H